Document Detail

n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study.
MedLine Citation:
PMID:  21059740     Owner:  NLM     Status:  MEDLINE    
AIMS: Persistent atrial fibrillation (AF) often recurs after direct current electrical cardioversion (ECV). As several experimental and clinical studies suggest that n-3 polyunsaturated fatty acids (PUFAs) may have antiarrhythmic properties even at the atrial level, we aimed to evaluate whether oral supplementation with PUFAs, in addition to conventional antiarrhythmic drugs, could reduce the recurrence rate of the arrhythmia after ECV of persistent AF.
METHODS AND RESULTS: Two hundred and four patients (mean age 69.3 years, 33% females) with persistent AF were randomly assigned to receive 3 g/day of PUFAs until ECV and 2 g/day thereafter (104 patients) or placebo (100 patients) for 6 months, beginning at least 1 week before ECV. Selection of conventional antiarrhythmic prophylaxis was left to local medical advice. The cardiac rhythm was assessed by both trans-telephonic monitoring and clinical visits. Primary end-point was the recurrence rate of AF. Sinus rhythm was restored, either spontaneously or after ECV, in 187 patients (91.7%); 95 patients (91.4%) on PUFAs and 92 patients (92.0%) on placebo (P=not significant). AF relapsed in 56 (58.9%) of the PUFAs patients and in 47 (51.1%) of the placebo patients (P=0.28). The mean time to AF recurrence was 83±8 days in the PUFAs group and 106±9 days in the placebo group (P=0.29).
CONCLUSION: Our results do not support the hypothesis that, in patients undergoing ECV of chronic persistent AF, supplementation with PUFAs in addition to the usual antiarrhythmic treatment reduces recurrent AF.
Leopoldo Bianconi; Leonardo Calò; Mauro Mennuni; Luca Santini; Paolo Morosetti; Paolo Azzolini; Giuseppe Barbato; Francesco Biscione; Paolo Romano; Massimo Santini
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2010-11-08
Journal Detail:
Title:  Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology     Volume:  13     ISSN:  1532-2092     ISO Abbreviation:  Europace     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-21     Completed Date:  2011-04-28     Revised Date:  2011-10-04    
Medline Journal Info:
Nlm Unique ID:  100883649     Medline TA:  Europace     Country:  England    
Other Details:
Languages:  eng     Pagination:  174-81     Citation Subset:  IM    
Department of Cardiology, San Filippo Neri Hospital, University of Tor Vergata, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Arrhythmia Agents / therapeutic use
Arrhythmias, Cardiac / prevention & control*
Atrial Fibrillation / therapy*
Chronic Disease
Dietary Supplements
Double-Blind Method
Drug Therapy, Combination
Electric Countershock / methods*
Fatty Acids, Omega-3 / administration & dosage,  blood,  therapeutic use*
Middle Aged
Recurrence / prevention & control
Treatment Outcome
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Fatty Acids, Omega-3
Comment In:
Europace. 2011 Sep;13(9):1357; author reply 1357-8   [PMID:  21561901 ]
Europace. 2011 Feb;13(2):149-52   [PMID:  21252194 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Improving estimates of specialist-diagnosed, work-related respiratory and skin disease.
Next Document:  Development of maternal seed tissue in barley is mediated by regulated cell expansion and cell disin...